top of page

Our Difference is the Science
Fueling Our Pipeline

The scientists of Ymmunobio are innovating cancer treatment with novel therapeutic antibodies. Our novel CEACAM1 antibody not only acts as a checkpoint inhibitor but also as an immune agonist, stimulating B- and T-cells to fight cancer.

Our first-in-class YB-800 antibody directly targets various cancers overexpressing New target receptor so that health tissue is not affected.



Our research into a new target receptor in oncology is focused on its development as a first-in-class ADC (antibody drug conjugate) target in GI cancers. Our fully humanized antibody binds to tumor cells selectively, and healthy tissue is not affected. 

The new target receptor was discovered through analyses of a large tumor bank.

ADC development work is currently ongoing.

Ymmunobio is in pre-clinical development focusing on GI cancers mainly with their platform supporting:

First in Class ADC Candidate YB-800ADC: indications in Solid Tumors.

Bi-Specific Candidate YB-800BS1 and YB-800BS2: indications in Solid Tumors.

Radio-labeled Candidate YB-800R1: indications in Solid Tumor

Radio-labeled Candidate YB-800R2: diagnostic tool to identify primary tumor and its


bottom of page